Somewhat Favorable Media Coverage Somewhat Unlikely to Affect AstraZeneca (AZN) Share Price

Media headlines about AstraZeneca (NYSE:AZN) have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AstraZeneca earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1281642195618 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of AstraZeneca (NYSE AZN) traded up $0.13 during trading hours on Thursday, hitting $35.40. 2,760,000 shares of the company’s stock were exchanged, compared to its average volume of 3,080,000. The firm has a market cap of $88,360.00, a price-to-earnings ratio of 25.29, a P/E/G ratio of 3.44 and a beta of 0.76. AstraZeneca has a 52 week low of $26.51 and a 52 week high of $35.92. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.32 EPS. sell-side analysts expect that AstraZeneca will post 1.88 earnings per share for the current year.

A number of equities analysts recently commented on the stock. Citigroup raised shares of AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $30.00 to $39.00 in a research note on Friday, September 22nd. Finally, Liberum Capital lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $34.20.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect AstraZeneca (AZN) Share Price” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/11/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-astrazeneca-azn-share-price.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Insider Buying and Selling by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit